Loading
Nutrition, Genetics, and Disease · Review
Medicina · August 6, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes mechanistic and secondary trial evidence to propose a four-phase CGM-guided prevention framework for apparently healthy non-diabetic adults at cardiovascular risk. The authors explicitly classify this as hypothesis-generating, emphasize the absence of prospective hard-endpoint trials, and call for rigorous outcome-based evaluation before clinical adoption.
Narrative review. Synthesis of evidence from prospective cohort studies, randomized controlled trials, and mechanistic investigations; target population is apparently healthy non-diabetic adults. Intervention: CGM-guided metabolic phenotyping combined with personalized dietary optimization, structured fasting protocols, and selective longevity-oriented pharmacotherapy (low-dose metformin, acarbose).
Postprandial glucose excursions promote endothelial injury and inflammatory pathways independently of mean glucose levels within normal glycemic range CGM-derived metrics capture inter-individual glycemic variability invisible to standard assessments Structured fasting and low-dose metformin converge on shared nutrient-sensing pathways implicated in vascular aging and longevity
Acarbose findings in non-diabetic populations explicitly not established; longevity-oriented pharmacotherapy remains unvalidated in healthy individuals
This framework should not yet be adopted as established clinical practice. Clinicians should recognize CGM as a research tool in this context pending rigorous prospective outcome trials; mechanistic coherence does not substitute for hard-endpoint evidence.
This is a narrative review proposing a hypothesis-generating framework for CGM-guided prevention in healthy adults; the authors explicitly state prospective hard-endpoint trials are lacking and the approach requires rigorous outcome-based evaluation before clinical adoption.
As stated by the source record.
This framework should not yet be adopted as established clinical practice. Clinicians should recognize CGM as a research tool in this context pending rigorous prospective outcome trials; mechanistic coherence does not substitute for hard-endpoint evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background and Objectives: Cardiovascular disease remains the leading cause of premature mortality worldwide. Subclinical glucose dysregulation, a contributor to accelerated vascular aging, is undetectable by conventional screening in apparently healthy individuals; even within the normal glycemic range, postprandial glucose excursions promote endothelial injury and inflammatory pathways independently of mean glucose levels. Hypothesis: Continuous glucose monitoring (CGM)-guided metabolic phenotyping, combined with personalized dietary optimization, structured fasting protocols, and selective longevity-oriented pharmacotherapy, constitutes a mechanistically coherent, hypothesis-generating preventive strategy that may attenuate cardiovascular risk and biological aging in apparently healthy non-diabetic adults, pending confirmation in prospective outcome trials. Materials and Methods: This narrative review synthesizes evidence from prospective cohort studies, randomized controlled trials, and mechanistic investigations connecting CGM-guided metabolic assessment with preventive cardiology and the emerging field of longevity medicine, focusing on glycemic variability biology, nutrient-sensing pathways, and the cardiovascular and longevity profiles of low-dose metformin and acarbose. Results: CGM-derived metrics capture inter-individual glycemic variability invisible to standard assessments and provide behavioral feedback for dietary personalization. Structured fasting and low-dose metformin converge on shared nutrient-sensing pathways implicated in both vascular aging and longevity, with CGM enabling objective confirmation of metabolic adaptation. Acarbose has shown cardiovascular and lifespan benefit signals in secondary trial analyses and preclinical longevity models, though these findings require replication and are not yet established in non-diabetic populations. Conclusions: We propose a four-phase research framework integrating CGM metabolic phenotyping, dietary optimization, fasting titration, and selective pharmacological augmentation for apparently healthy adults at cardiovascular risk. Prospective hard-endpoint trials are lacking, and this framework should be regarded as hypothesis-generating rather than an established clinical strategy, warranting rigorous outcome-based evaluation before clinical adoption.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.